869 related articles for article (PubMed ID: 33606519)
1. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
Prasad K; Ahamad S; Kanipakam H; Gupta D; Kumar V
ACS Chem Neurosci; 2021 Mar; 12(5):930-944. PubMed ID: 33606519
[TBL] [Abstract][Full Text] [Related]
2. Genomics-guided identification of potential modulators of SARS-CoV-2 entry proteases, TMPRSS2 and Cathepsins B/L.
Prasad K; AlOmar SY; Almuqri EA; Rudayni HA; Kumar V
PLoS One; 2021; 16(8):e0256141. PubMed ID: 34407143
[TBL] [Abstract][Full Text] [Related]
3. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.
Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A
Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606
[TBL] [Abstract][Full Text] [Related]
4. Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection.
Padmanabhan P; Desikan R; Dixit NM
PLoS Comput Biol; 2020 Dec; 16(12):e1008461. PubMed ID: 33290397
[TBL] [Abstract][Full Text] [Related]
5. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K
Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650
[TBL] [Abstract][Full Text] [Related]
6. Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2.
Li Y; Wang K; Sun H; Wu S; Wang H; Shi Y; Li X; Yan H; Yang G; Wu M; Li Y; Ding X; Si S; Jiang J; Du Y; Li Y; Hong B
Antiviral Res; 2023 Jun; 214():105606. PubMed ID: 37076089
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Eur J Pharmacol; 2021 Apr; 896():173922. PubMed ID: 33539819
[TBL] [Abstract][Full Text] [Related]
8. Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion.
Kaur U; Chakrabarti SS; Ojha B; Pathak BK; Singh A; Saso L; Chakrabarti S
Curr Drug Targets; 2021; 22(2):192-201. PubMed ID: 32972339
[TBL] [Abstract][Full Text] [Related]
9. Modelling how increased Cathepsin B/L and decreased TMPRSS2 usage for cell entry by the SARS-CoV-2 Omicron variant may affect the efficacy and synergy of TMPRSS2 and Cathepsin B/L inhibitors.
Padmanabhan P; Dixit NM
J Theor Biol; 2023 Sep; 572():111568. PubMed ID: 37393986
[TBL] [Abstract][Full Text] [Related]
10. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
13. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
14. Multiple sites on SARS-CoV-2 spike protein are susceptible to proteolysis by cathepsins B, K, L, S, and V.
Bollavaram K; Leeman TH; Lee MW; Kulkarni A; Upshaw SG; Yang J; Song H; Platt MO
Protein Sci; 2021 Jun; 30(6):1131-1143. PubMed ID: 33786919
[TBL] [Abstract][Full Text] [Related]
15. Reactive Centre Loop Mutagenesis of SerpinB3 to Target TMPRSS2 and Furin: Inhibition of SARS-CoV-2 Cell Entry and Replication.
Singh S; O'Reilly S; Gewaid H; Bowie AG; Gautier V; Worrall DM
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293378
[TBL] [Abstract][Full Text] [Related]
16. TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells.
Koch J; Uckeley ZM; Doldan P; Stanifer M; Boulant S; Lozach PY
EMBO J; 2021 Aug; 40(16):e107821. PubMed ID: 34159616
[TBL] [Abstract][Full Text] [Related]
17. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
Muralidar S; Gopal G; Visaga Ambi S
J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models.
Mykytyn AZ; Breugem TI; Geurts MH; Beumer J; Schipper D; van Acker R; van den Doel PB; van Royen ME; Zhang J; Clevers H; Haagmans BL; Lamers MM
J Virol; 2023 Aug; 97(8):e0085123. PubMed ID: 37555660
[TBL] [Abstract][Full Text] [Related]
19. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
20. MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L.
Ma XR; Alugubelli YR; Ma Y; Vatansever EC; Scott DA; Qiao Y; Yu G; Xu S; Liu WR
ChemMedChem; 2022 Jan; 17(1):e202100456. PubMed ID: 34242492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]